Donald McDonnell: A Summary of the Biology of Endocrine Therapy Resistance in Breast Cancer
Donald McDonnell, Professor at the Department of Pharmacology and Cancer Biology at Duke University School of Medicine, shared a post on LinkedIn about a recent article by François-Clément Bidard et al. published in NEJM:
“This is a very clear summary of the complex biology underlying resistance to endocrine therapies (aromatase inhibitors) in patients with breast cancer.”
Title: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
Authors: François-Clément Bidard, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen Chia, Peter A. Fasching, Adam Brufsky, Zbigniew Nowecki, Javier Pascual, Lionel Moreau, Shin-Cheh Chen, Nuri Karadurmus, Einav Nili Gal-Yam, Kyung Hae Jung, Sonia Pernas, Sasha McClain, Wei He, Teresa Klinowska, Cynthia Huang-Bartlett, Nicholas C. Turner
Read the Full Article on NEJM
More posts featuring Donald McDonnell.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023